Skip to main content
Log in

Natural history of Sanfilippo syndrome type A

  • Original Article
  • Published:
Journal of Inherited Metabolic Disease

Abstract

Objective

To describe the natural history of Sanfilippo syndrome type A.

Methods

We performed a retrospective review of 46 children (21 boys, 25 girls) with Sanfilippo syndrome type A evaluated between January 2000 and April 2013. Assessments included neurodevelopmental evaluations, audiologic testing, and assessment of growth, adaptive behavior, cognitive behavior, motor function, and speech/language skills. Only the baseline evaluation was included for patients who received hematopoietic stem cell transplantation.

Results

Median age at diagnosis was 35 months, with a median delay between initial symptoms to diagnosis of 24 months. The most common initial symptoms were speech/language delay (48 %), dysmorphology (22 %), and hearing loss (20 %). Early behavioral problems included perseverative chewing and difficulty with toilet training. All children developed sleep difficulties and behavioral changes (e.g., hyperactivity, aggression). More than 93 % of the children experienced somatic symptoms such as hepatomegaly (67 %), abnormal dentition (39 %), enlarged tongue (37 %), coarse facial features (76 %), and protuberant abdomen (43 %). Kaplan-Meier analysis showed a 60 % probability of surviving past 17 years of age.

Conclusions

Sanfilippo type A is characterized by severe hearing loss and speech delay, followed by a rapid decline in cognitive skills by 3 years of age. Significant somatic disease occurs in more than half of patients. Behavioral difficulties presented between 2 and 4 years of age during a rapid period of cognitive decline. Gross motor abilities are maintained during this period, which results in an active child with impaired cognition. Sleep difficulties are concurrent with the period of cognitive degeneration. There is currently an unacceptable delay in diagnosis, highlighting the need to increase awareness of this disease among clinicians.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Baehner F, Schmiedeskamp C, Krummenauer F et al (2005) Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 28:1011–1017

    Article  CAS  PubMed  Google Scholar 

  • Bruininks R, Woodcock R, Weatherman R, Hill B (1996) Scales of independent behaviour-revised. Riverside, Chicago

    Google Scholar 

  • Cleary MA, Wraith JE (1993) Management of mucopolysaccharidosis type III. Arch Dis Child 69:403–406

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Crawley AC, Marshall N, Beard H et al (2011) Enzyme replacement reduces neuropathology in MPS IIIA dogs. Neurobiol Dis 43:422–434

    Article  CAS  PubMed  Google Scholar 

  • Elliott CD (1990) The Differential Ability Scales (DAS). The Psychological Corp, San Antonio

    Google Scholar 

  • Folio M, Fewell R (2000) Peabody developmental motor scales, 2nd edn. Pro-Ed, Austin

    Google Scholar 

  • Haurigot V, Marco S, Ribera A et al (2013) Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest. doi:10.1172/JCI66778

    PubMed Central  PubMed  Google Scholar 

  • Héron B, Mikaeloff Y, Froissart R et al (2011) Incidence and natural history ofmucopolysaccharidosis type III in France and comparison with United Kingdom and Greece. Am J Med Genet A 155A:58–68

    Article  PubMed  Google Scholar 

  • Kuczmarski RJ, Ogden CL, Guo SS et al (2002) 2000 CDC growth charts for the United States: methods and development. National Center for Health Statistics. Vital Health Stat 11:246

    Google Scholar 

  • Langford-Smith A, Wilkinson FL, Langford-Smith KJ et al (2012) Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice. Mol Ther: J Am Soc Gene Ther 20:1610–1621

    Article  CAS  Google Scholar 

  • Malm G, Mansson JE (2010) Mucopolysaccharidosis type III (Sanfilippo disease) in Sweden: clinical presentation of 22 children diagnosed during a 30-year period. Acta Paediatr 99:1253–1257

    Article  CAS  PubMed  Google Scholar 

  • Martin HR, Poe MD, Reinhartsen D et al (2008) Methods for assessing neurodevelopment in lysosomal storage diseases and related disorders: a multidisciplinary perspective. Acta Paediatr Suppl 97:69–75

    Article  PubMed  Google Scholar 

  • Meyer A, Kossow K, Gal A et al (2007) Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A). Pediatrics 120:e1255–e1261

    Article  PubMed  Google Scholar 

  • Meyer A, Kossow K, Gal A et al (2008) The mutation p.Ser298Pro in the sulphamidase gene (SGSH) is associated with a slowly progressive clinical phenotype in mucopolysaccharidosis type IIIA (Sanfilippo A syndrome). Hum Mutat 29:770

    Article  PubMed  Google Scholar 

  • Mullen E (1995) The mullen scales of early learning. American Guidance Service, Circle Pines

    Google Scholar 

  • Piotrowska E, Jakobkiewicz-Banecka J, Maryniak A et al (2011) Two-year follow-up of Sanfilippo Disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients. Med Sci Monit 17:CR196–CR202

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Prasad VK, Mendizabal A, Parikh SH, Szabolcs P et al (2008) Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes. Blood 112:2979–2989

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Semel E, Wiig E, Secord W (2003) Clinical evaluation of language fundamentals, 4th edn. The Psychological Corporation, San Antonio

    Google Scholar 

  • Valstar MJ, Ruijter GJ, van Diggelen OP, Poorthuis BJ, Wijburg FA (2008) Sanfilippo syndrome: a mini-review. J Inherit Metab Dis 31:240–252

    Article  CAS  PubMed  Google Scholar 

  • Valstar MJ, Neijs S, Bruggenwirth HT et al (2010) Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann Neurol 68:876–887

    Article  PubMed  Google Scholar 

  • Van de Kamp JJ, Niermeijer MF, von Figura K, Giesberts MA (1981) Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C). Clin Genet 20:152–160

    Article  PubMed  Google Scholar 

  • Yogalingam G, Hopwood JJ (2001) Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: diagnostic, clinical, and biological implications. Hum Mutat 18:264–281

    Article  CAS  PubMed  Google Scholar 

  • Zimmerman I, Steiner V, Pond R (2002) Preschool language scale, 4th edn. The Psychological Corp, San Antonio

    Google Scholar 

Download references

Competing interest

Dr. Escolar is a consultant for Shire Human. The content of the article has not been influenced by the sponsors.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Maria L. Escolar.

Additional information

Communicated by: Frits Wijburg

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buhrman, D., Thakkar, K., Poe, M. et al. Natural history of Sanfilippo syndrome type A. J Inherit Metab Dis 37, 431–437 (2014). https://doi.org/10.1007/s10545-013-9661-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10545-013-9661-8

Keywords

Navigation